| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Emergent Biosolutions Inc. (EBS) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 15 sells. EBS is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 374.1K | $3.11M | - | |
| CEO | 305.4K | $2.54M | - | |
| VP | 202.2K | $1.68M | - | |
| VP | 185.6K | $1.54M | - | |
| VP | 162.1K | $1.35M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 7, 2017 | Joulwan George A | Director | Sale+OE | 14,251 | $41.24 | $587,711.24 | -19.0% | |
| Nov 3, 2017 | Abdun-Nabi Daniel | President &CEO | Sale+OE | 31,508 | $42.77 | $1,347,490.00 | -7.2% | |
| Sep 29, 2017 | El-Hibri Fuad | Chairman | Sell | 50,000 | $40.00 | $2,000,000.00 | -1.6% | |
| Sep 28, 2017 | Richard Ronald | Director | Sale+OE | 23,681 | $40.00 | $947,240.00 | -33.6% | |
| Sep 27, 2017 | Abdun-Nabi Daniel | President &CEO | Sale+OE | 15,000 | $39.92 | $598,770.00 | -6.8% | |
| Sep 27, 2017 | Havey Adam | EVP, Business Operations | Sale+OE | 7,885 | $39.50 | $311,457.50 | -23.2% | |
| Sep 14, 2017 | El-Hibri Fuad | Chairman | Sell | 25,000 | $38.50 | $962,500.00 | -0.8% | |
| Sep 8, 2017 | Havey Adam | EVP, Business Operations | Sale+OE | 7,885 | $37.06 | $292,242.54 | -23.2% | |
| Sep 7, 2017 | El-Hibri Fuad | Chairman | Sell | 16,439 | $37.50 | $616,462.50 | -1.0% | |
| Sep 5, 2017 | El-Hibri Fuad | Chairman | Sell | 3,100 | $37.50 | $116,250.00 | -0.2% |